Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer

Table 3 Clinical incidence of ≥ G2 late toxicity and NTCP calculations

	A	B
Clinical incidence	14.0%	12.3%
NTCP (prior to optimization) TD₅₀ = 80 Gy, α/β = 3 Gy	10 ± 3%	6 ± 2%
NTCP (after optimization) TD₅₀ = 76 Gy, α/β = 2.3 Gy	15 ± 5%	12 ± 4%

ISSN: 1756-9966